Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome

S. Manzo-Silberman, P. Guedeney, G. Cayla, F. Beygui, G. Rangé, Z. Motovska, N. Procopi, M. Kerneis, M. Zeitouni, M. El Kasty, E. Teiger, E. Filippi, P. Coste, F. Huchet, Y. Cottin, J. Karasek, MA. Arnould, N. Braik, O. Barthelemy, JJ. Portal, E....

. 2024 ; 17 (12) : 1413-1421. [pub] 20240605

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, srovnávací studie, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013458

BACKGROUND: Whether ticagrelor may reduce periprocedural myocardial necrosis after elective percutaneous coronary intervention (PCI) in patients with and without chronic clopidogrel therapy is unclear. OBJECTIVES: This study sought to compare ticagrelor vs clopidogrel in patients with and without chronic clopidogrel therapy before undergoing elective PCI. METHODS: In this prespecified analysis of the ALPHEUS (Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting) trial, patients were defined as clopidogrel(+) and clopidogrel(-) according to the presence and absence of clopidogrel treatment for ≥7 days before PCI, respectively. The primary endpoint was the composite of PCI-related myocardial infarction and major injury as defined by the third and fourth universal definition 48 hours after PCI. RESULTS: A total of 1,882 patients were included, 805 (42.7%) of whom were clopidogrel(+). These patients were older, had more comorbidities, and had more frequent features of complex PCI. The primary endpoint was less frequently present in clopidogrel(-) compared to clopidogrel(+) patients (32.8% vs 40.0%; OR: 0.73; 95% CI: 0.60-0.88), but no significant differences were reported for the risk of death, myocardial infarction, stroke, or transient ischemic attack at 48 hours or 30 days. Ticagrelor did not reduce periprocedural myocardial necrosis or the risk of adverse outcomes, and there was no significant interaction regarding the presence of chronic clopidogrel treatment. CONCLUSIONS: Clopidogrel-naive patients presented less periprocedural complications compared to clopidogrel(+) patients, a difference related to a lower risk profile and less complex PCI. The absence of clopidogrel at baseline did not affect the absence of a difference between ticagrelor and clopidogrel in terms of PCI-related complications supporting the use of clopidogrel as the standard of care in elective PCI in patients with or without chronic clopidogrel treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013458
003      
CZ-PrNML
005      
20240905134243.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcin.2024.04.015 $2 doi
035    __
$a (PubMed)38842993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Manzo-Silberman, Stéphane $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
245    10
$a Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome / $c S. Manzo-Silberman, P. Guedeney, G. Cayla, F. Beygui, G. Rangé, Z. Motovska, N. Procopi, M. Kerneis, M. Zeitouni, M. El Kasty, E. Teiger, E. Filippi, P. Coste, F. Huchet, Y. Cottin, J. Karasek, MA. Arnould, N. Braik, O. Barthelemy, JJ. Portal, E. Vicaut, G. Montalescot, J. Silvain, ALPHEUS Investigators
520    9_
$a BACKGROUND: Whether ticagrelor may reduce periprocedural myocardial necrosis after elective percutaneous coronary intervention (PCI) in patients with and without chronic clopidogrel therapy is unclear. OBJECTIVES: This study sought to compare ticagrelor vs clopidogrel in patients with and without chronic clopidogrel therapy before undergoing elective PCI. METHODS: In this prespecified analysis of the ALPHEUS (Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting) trial, patients were defined as clopidogrel(+) and clopidogrel(-) according to the presence and absence of clopidogrel treatment for ≥7 days before PCI, respectively. The primary endpoint was the composite of PCI-related myocardial infarction and major injury as defined by the third and fourth universal definition 48 hours after PCI. RESULTS: A total of 1,882 patients were included, 805 (42.7%) of whom were clopidogrel(+). These patients were older, had more comorbidities, and had more frequent features of complex PCI. The primary endpoint was less frequently present in clopidogrel(-) compared to clopidogrel(+) patients (32.8% vs 40.0%; OR: 0.73; 95% CI: 0.60-0.88), but no significant differences were reported for the risk of death, myocardial infarction, stroke, or transient ischemic attack at 48 hours or 30 days. Ticagrelor did not reduce periprocedural myocardial necrosis or the risk of adverse outcomes, and there was no significant interaction regarding the presence of chronic clopidogrel treatment. CONCLUSIONS: Clopidogrel-naive patients presented less periprocedural complications compared to clopidogrel(+) patients, a difference related to a lower risk profile and less complex PCI. The absence of clopidogrel at baseline did not affect the absence of a difference between ticagrelor and clopidogrel in terms of PCI-related complications supporting the use of clopidogrel as the standard of care in elective PCI in patients with or without chronic clopidogrel treatment.
650    _2
$a lidé $7 D006801
650    12
$a klopidogrel $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D000077144
650    12
$a ticagrelor $x škodlivé účinky $x terapeutické užití $7 D000077486
650    12
$a koronární angioplastika $x škodlivé účinky $x mortalita $7 D062645
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    12
$a inhibitory agregace trombocytů $x škodlivé účinky $x terapeutické užití $7 D010975
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a časové faktory $7 D013997
650    _2
$a rizikové faktory $7 D012307
650    12
$a infarkt myokardu $x mortalita $7 D009203
650    _2
$a chronická nemoc $7 D002908
650    _2
$a antagonisté purinergních receptorů P2Y $x škodlivé účinky $x terapeutické užití $7 D058921
650    _2
$a nekróza $7 D009336
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a nemoci koronárních tepen $x terapie $x mortalita $x diagnostické zobrazování $x farmakoterapie $7 D003324
650    _2
$a stenty $7 D015607
650    _2
$a krvácení $x chemicky indukované $7 D006470
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Guedeney, Paul $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Cayla, Guillaume $u Cardiology Department, Nîmes University Hospital, Montpellier University, ACTION Study Group, Nîmes, France
700    1_
$a Beygui, Farzin $u Cardiology Department, Caen University Hospital, Normandie University, ACTION Study Group, Caen, France
700    1_
$a Rangé, Grégoire $u Cardiology Department, Chartres Hospital, Chartres, France
700    1_
$a Motovska, Zuzana $u 3rd Faculty of Medicine, Charles University and Cardiocentre University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Procopi, Niki $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Kerneis, Mathieu $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Zeitouni, Michel $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a El Kasty, Mohamad $u Cardiology Department, Grand Hôpital de l'Est Francilien, Jossigny, France
700    1_
$a Teiger, Emmanuel $u Cardiology Department, Henri-Mondor Hospital (AP-HP), Créteil, France
700    1_
$a Filippi, Emmanuelle $u Cardiology Department, Bretagne-Atlantique Hospital, Vannes, France
700    1_
$a Coste, Pierre $u Cardiology Department, Bordeaux University Hospital, Pessac, France
700    1_
$a Huchet, François $u Cardiology Department, Saint-Nazaire Hospital, Saint-Nazaire, France
700    1_
$a Cottin, Yves $u Cardiology Department, CHU Dijon Bourgogne, Dijon, France
700    1_
$a Karasek, Jiří $u Cardiology Department, Liberec Hospital, Liberec, Czech Republic; 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Arnould, Marc-Antoine $u Service de Cardiologie, Clinique Saint-Gatien, Saint-Cyr-sur-Loire, France
700    1_
$a Braik, Nassim $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Barthelemy, Olivier $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Portal, Jean-Jacques $u ACTION Study Group, Unité de Recherche Clinique, Lariboisière Hospital, AP-HP, Paris, France
700    1_
$a Vicaut, Eric $u ACTION Study Group, Unité de Recherche Clinique, Lariboisière Hospital, AP-HP, Paris, France
700    1_
$a Montalescot, Gilles $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
700    1_
$a Silvain, Johanne $u Sorbonne Université, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: johanne.silvain@aphp.fr
710    2_
$a ALPHEUS Investigators
773    0_
$w MED00186218 $t JACC. Cardiovascular interventions $x 1876-7605 $g Roč. 17, č. 12 (2024), s. 1413-1421
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38842993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134237 $b ABA008
999    __
$a ok $b bmc $g 2143340 $s 1225324
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 17 $c 12 $d 1413-1421 $e 20240605 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace